Holen Sie sich die Stockscreener-App
32.17
2.01%
-0.66
Schlusskurs vom Vortag:
$32.83
Offen:
$33.33
24-Stunden-Volumen:
276.26K
Relative Volume:
0.72
Marktkapitalisierung:
$1.54B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-107.28M
KGV:
-12.36
EPS:
-2.6031
Netto-Cashflow:
$-80.71M
1W Leistung:
-5.13%
1M Leistung:
-33.93%
6M Leistung:
-4.20%
1J Leistung:
+12.72%
1-Tages-Spanne:
$31.77
$34.48
1-Wochen-Bereich:
$31.77
$34.48
52-Wochen-Spanne:
$23.75
$52.93
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Firmenname
Rapport Therapeutics Inc
Sektor
Branche
Telefon
857-321-8020
Adresse
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
32.17 | 1.63B | 0 | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-02 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-09-16 | Eingeleitet | Truist | Buy |
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-08 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Eingeleitet | Jefferies | Buy |
| 2024-07-02 | Eingeleitet | Stifel | Buy |
| 2024-07-02 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Rapport Therapeutics Inc Aktie (RAPP) Neueste Nachrichten
Form 144 Rapport Therapeutics For: 1 October By Investing.com - Investing.com Canada
RAPP 10-Q FilingsRapport Therapeutics, Inc. SEC 10-Q - Stock Titan
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Show Me The Money: Rapport Stock Up Over 400% In 16 Months; Bipolar Mania Data Next - RTTNews
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Nigeria
Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Form 4 Rapport Therapeutics Inc For: 24 September - Investing.com India
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com
Rapport Therapeutics shares drop 18% on updates for RAP-219 and upcoming bipolar mania trial data - Pluang
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure MedRating Upgrade - Seeking Alpha
Analysts Conflicted on These NA Names: General Dynamics (GD), Rapport Therapeutics, Inc. (RAPP) and First Solar (FSLR) - The Globe and Mail
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar ManiaSlideshow - Seeking Alpha
Why is Rapport Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Rapport Therapeutics at TD Cowen summit: bipolar data loom By Investing.com - Investing.com Canada
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success - Seeking Alpha
Citizens reiterates Rapport Therapeutics stock rating on Phase 2 trial potential - Investing.com Canada
Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Rapport Therapeutics stock - Investing.com
RAPP: RAP-219 targets TARPγ8 for bipolar mania, aiming to address major unmet needs with a novel approach - TradingView
4 Biotech Stocks With Key Clinical Readouts Expected This Fall - TradingView
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potential - DirectorsTalk Interviews
RAPPORT THERAPEUTICS, INC. : BTIG RAISES TARGET PRICE TO $75 FROM $65 - webull.com
Why Rapport Therapeutics’ Hot Rally Is Cooling - TipRanks
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $50 to $75 - Moomoo
Rapport Therapeutics Is Maintained at Buy by BTIG - Moomoo
Stifel Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
BTIG maintains Buy rating on Rapport Therapeutics, $75 price target - TradingView
(RAPP) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Truist reiterates Buy on Rapport Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Rapport Therapeutics stock ahead of data - Investing.com
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Australia
Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares - Bitget
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock - investing.com
Rapport Therapeutics Slides As Rally Loses Steam - TipRanks
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RAPP 8-K FilingsRapport Therapeutics, Inc. SEC 8-K - Stock Titan
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - moomoo.com
Rapport Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportRisk Reversal - dars.gov.et
Rapport Therapeutics CEO Abraham Ceesay Sells 18,921 Shares Under Rule 10b5-1 Plan - Kalkine Media
Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades - stocktitan.net
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program - Barchart.com
Rapport Therapeutics' RAP-219 shows promise wit... - Pluang
Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise - Seeking Alpha
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 404 Shares - MarketBeat
Rapport Therapeutics CDO Sells 404 Shares Under Rule 10b5-1 Trading Plan - Kalkine Media
Does Widening Losses And Higher EPS Drag Change The Bull Case For Rapport Therapeutics (RAPP)? - simplywall.st
Finanzdaten der Rapport Therapeutics Inc-Aktie (RAPP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):